Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Invested Capital: 2012-2024

Historic Invested Capital for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $1.1 billion.

  • Amphastar Pharmaceuticals' Invested Capital rose 4.57% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 4.57%. This contributed to the annual value of $1.1 billion for FY2024, which is 9.43% up from last year.
  • According to the latest figures from FY2024, Amphastar Pharmaceuticals' Invested Capital is $1.1 billion, which was up 9.43% from $984.4 million recorded in FY2023.
  • Amphastar Pharmaceuticals' Invested Capital's 5-year high stood at $1.1 billion during FY2024, with a 5-year trough of $457.4 million in FY2020.
  • Moreover, its 3-year median value for Invested Capital was $984.4 million (2023), whereas its average is $886.2 million.
  • Data for Amphastar Pharmaceuticals' Invested Capital shows a peak YoY skyrocketed of 64.92% (in 2023) over the last 5 years.
  • Over the past 5 years, Amphastar Pharmaceuticals' Invested Capital (Yearly) stood at $457.4 million in 2020, then rose by 12.60% to $515.1 million in 2021, then rose by 15.89% to $596.9 million in 2022, then soared by 64.92% to $984.4 million in 2023, then rose by 9.43% to $1.1 billion in 2024.